UPDATE: Transition Therapeutics Announces Placement for Up to $30.8M in Equity, Will Get Upfront Payment $17M
Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) announced that Jack W. Schuler, Larry N. Feinberg, Oracle Investment Management, certain Transition Board members, management and other existing shareholders will make an investment of up to US$30.8 million by purchasing 3,195,487 units of the Company at a price of US$5.32 per unit.
Each unit consists of one common share, and 0.61 of a common share purchase warrant with a purchase price of US$7.10 per whole warrant. Each whole warrant will entitle the holder, within two years from closing, to purchase one additional common share in the capital of the Company. If and when all of the warrants are exercised, the Company will realize an additional US$13.8 million, bringing the total investment to US$30.8 million before transaction costs. Closing of the private placement is expected to occur on or about June 20, 2014 and is subject to approval from the Toronto Stock Exchange.
"With this offering, Transition has sufficient funding to complete its Phase 2 clinical study of drug candidate ELND005 in agitation and aggression associated with Alzheimer's disease and the Phase 2 clinical study of drug candidate TT-401 (LY2944876) in type 2 diabetes. Building on these core development programs, this offering will enable the Company to expand its pipeline of drug candidates in-licensed through partnerships with pharmaceutical companies. I am very pleased with the on-going commitment and support of our large investors, Board and management that contributed to the financing of the offering," said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition.
These securities have not been registered under the U.S. Securities Act of 1933, as amended (the "Act"), and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.